PROCEPT BioRobotics Corporation

NasdaqGM:PRCT 株式レポート

時価総額:US$4.1b

このページの翻訳は実験的なもので、現在開発中です。お待ちしております

PROCEPT BioRobotics 将来の成長

Future 基準チェック /26

PROCEPT BioRoboticsは、40.8%と24.5%でそれぞれ年率40.8%で利益と収益が成長すると予測される一方、EPSはgrowで43%年率。

主要情報

41.4%

収益成長率

42.8%

EPS成長率

Medical Equipment 収益成長17.8%
収益成長率24.6%
将来の株主資本利益率n/a
アナリストカバレッジ

Good

最終更新日21 Aug 2024

今後の成長に関する最新情報

Here's What Analysts Are Forecasting For PROCEPT BioRobotics Corporation (NASDAQ:PRCT) After Its Second-Quarter Results

Aug 04
Here's What Analysts Are Forecasting For PROCEPT BioRobotics Corporation (NASDAQ:PRCT) After Its Second-Quarter Results

US$56.67 - That's What Analysts Think PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Is Worth After These Results

Mar 01
US$56.67 - That's What Analysts Think PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Is Worth After These Results

Recent updates

Procept BioRobotics: Risk Capital Unlock With FDA Hydros Approval

Aug 27

Investors Appear Satisfied With PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) Prospects As Shares Rocket 28%

Aug 25
Investors Appear Satisfied With PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) Prospects As Shares Rocket 28%

Here's What Analysts Are Forecasting For PROCEPT BioRobotics Corporation (NASDAQ:PRCT) After Its Second-Quarter Results

Aug 04
Here's What Analysts Are Forecasting For PROCEPT BioRobotics Corporation (NASDAQ:PRCT) After Its Second-Quarter Results

PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) P/S Is Still On The Mark Following 37% Share Price Bounce

May 21
PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) P/S Is Still On The Mark Following 37% Share Price Bounce

The Price Is Right For PROCEPT BioRobotics Corporation (NASDAQ:PRCT)

Apr 05
The Price Is Right For PROCEPT BioRobotics Corporation (NASDAQ:PRCT)

US$56.67 - That's What Analysts Think PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Is Worth After These Results

Mar 01
US$56.67 - That's What Analysts Think PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Is Worth After These Results

Despite Lacking Profits PROCEPT BioRobotics (NASDAQ:PRCT) Seems To Be On Top Of Its Debt

Feb 07
Despite Lacking Profits PROCEPT BioRobotics (NASDAQ:PRCT) Seems To Be On Top Of Its Debt

Market Participants Recognise PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) Revenues Pushing Shares 26% Higher

Dec 14
Market Participants Recognise PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) Revenues Pushing Shares 26% Higher

Is There An Opportunity With PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) 43% Undervaluation?

Feb 27
Is There An Opportunity With PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) 43% Undervaluation?

Procept Biorobotics announces $52M debt refinancing

Oct 10

Providence announces national contract for PROCEPT Biorobotics Aquabeam Systems

Sep 19

Procept BioRobotics Has Resources To Ramp Up Commercialization

Sep 01

Procept: Leveraging A Novel Water-Based System For Enlarged Prostate Treatment

May 26

Need To Know: Analysts Are Much More Bullish On PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Revenues

May 10
Need To Know: Analysts Are Much More Bullish On PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Revenues

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Just Reported, And Analysts Assigned A US$41.00 Price Target

Mar 10
PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Just Reported, And Analysts Assigned A US$41.00 Price Target

業績と収益の成長予測

NasdaqGM:PRCT - アナリストの将来予測と過去の財務データ ( )USD Millions
日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数
12/31/2026396-48N/AN/A4
12/31/2025305-77-66N/A7
12/31/2024217-97-69N/A7
6/30/2024177-104-109-92N/A
3/31/2024156-103-126-104N/A
12/31/2023136-106-133-108N/A
9/30/2023116-107-126-108N/A
6/30/2023102-105-122-109N/A
3/31/202385-98-106-98N/A
12/31/202275-87-83-80N/A
9/30/202261-77-74-72N/A
6/30/202250-69-65-65N/A
3/31/202241-64-61-60N/A
12/31/202134-60-58-57N/A
9/30/202128-57-55-54N/A
6/30/202121-55-53-52N/A
3/31/202114-53-52-52N/A
12/31/20208-53-49-48N/A
12/31/20196-42-51-44N/A

アナリストによる今後の成長予測

収入対貯蓄率: PRCT今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: PRCT今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: PRCT今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: PRCTの収益 ( 24.5% ) US市場 ( 8.7% ) よりも速いペースで成長すると予測されています。

高い収益成長: PRCTの収益 ( 24.5% ) 20%よりも速いペースで成長すると予測されています。


一株当たり利益成長率予想


将来の株主資本利益率

将来のROE: PRCTの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です


成長企業の発掘